C-OBIETrivium Vet
veterinary therapeutics, mTOR inhibition, sirolimus
modulatingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-OBIE
C-OBIEC-OBIEveterinary therapeutics, mTOR inhibition, sirolimus
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Trivium Vet veterinary therapeutics, mTOR inhibition, sirolimus
TriviumVet is an animal health company developing therapeutic solutions for unmet needs in pet diseases. Its programs address cardiology, gastroenterology, chronic kidney disease, age-related decline, and pain management in cats and dogs. The company lists Felycin-CA1 as a conditionally approved treatment for ventricular hypertrophy in cats with subclinical hypertrophic cardiomyopathy.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
Trivium Vet — Near-term readout · Lower middle. Derived deterministically from 10 extracted project(s). Most-advanced status: approved. Band: near_readout. Aging-relevance not LLM-reviewed in this pass.
Source: Deterministic